



# Yuhan Corporation

---

2025. 1Q


# Corporate Profile



◆ Date of foundation	20 June 1926
◆ Date of IPO	1 November 1962
◆ Founder	Il Han New
◆ Major shareholder	Yuhan Foundation(15.82%)
◆ Number of employees	2,117(As of the end of 2024)
◆ Headquarter location	Dongjak-gu, Seoul Korea
◆ Plant location	Cheongju-si, Chungcheongbuk-do
◆ Reasearch center location	Yongin-si, Gyeonggi-do

# Business Status

# Business Portfolio



# Separate financial statement - Yearly results

[Unit : KRW in million]

Section		2022			2023			2024		
		Amount	Ratio	YoY	Amount	Ratio	YoY	Amount	Ratio	YoY
Pharmaceutical Business	OTC	195,820	11.3%	19.7%	193,702	10.7%	-1.1%	205,885	10.3%	6.3%
	Prescription	1,115,401	64.6%	10.0%	1,138,577	62.9%	2.1%	1,141,942	56.9%	0.3%
	Total	1,311,221	76.0%	11.3%	1,332,279	73.6%	1.6%	1,347,827	67.1%	1.2%
Consumer Goods & Healthcare		181,279	10.5%	-13.9%	215,284	11.9%	18.8%	240,621	12.0%	11.8%
Overseas Business		212,808	12.3%	23.5%	241,150	13.3%	13.3%	306,484	15.3%	27.1%
License income		8,745	0.5%	-83.1%	11,235	0.6%	28.5%	105,237	5.2%	836.7%
Others(Lease & Services)		12,312	0.7%	6.3%	9,134	0.5%	-25.8%	8,186	0.4%	-10.4%
Net Sales		1,726,365	100.0%	6.3%	1,809,082	100.0%	4.8%	2,008,355	100.0%	11.0%
Operating Profit		41,120	2.4%	-32.8%	57,207	3.2%	39.1%	70,106	3.5%	22.5%
Profit before income tax		153,966	8.9%	12.5%	100,122	5.5%	-35.0%	111,083	5.5%	10.9%
Net Income		130,274	7.5%	14.4%	95,413	5.3%	-26.8%	96,713	4.8%	1.4%

※ This report is prepared to give investors a better understanding of Yuhan Corporation.

Data in this report subject to change. Copyright © 2025 by YUHAN. All rights Reserved.

# Separate financial statement - Quarterly Results

[Unit : KRW in million]

Section		1Q25	YoY	1Q24	2Q25	YoY	2Q24	3Q25	YoY	3Q24	4Q25	YoY	4Q24
Pharmaceutical Business	OTC	54,313	15.8%	46,907			52,365			52,867			53,746
	Prescription	275,468	4.9%	262,621			286,721			294,980			297,620
	Total	329,781	6.5%	309,528			339,086			347,847			351,366
Consumer Goods & Healthcare		46,741	5.1%	44,454			75,220			67,430			53,517
Overseas Business		87,363	17.9%	74,107			97,180			70,067			65,130
License income		3,976	56.0%	2,549			555			98,170			3,963
Others(Lease & Services)		1,551	-38.2%	2,509			2,585			1,653			1,439
Net Sales		469,412	8.4%	433,147			514,626			585,167			475,415
R&D costs		50,199	9.9%	45,683			53,457			90,266			64,734
Operating Profit		8,645	40.8%	6,142			15,731			54,466		-	6,233
Margin %		1.8%		1.4%			3.1%			9.3%			13.6%
Dividend Income		35,045	13.4%	30,900									22,500
Profit before income tax		43,426	6.5%	40,788			30,016			38,198			2,081
Net Income		39,331	8.1%	36,369			24,525			23,729			12,089
Margin %		8.4%		8.4%			4.8%			4.1%			2.5%

※ This report is prepared to give investors a better understanding of Yuhan Corporation.

Data in this report subject to change. Copyright © 2025 by YUHAN. All rights Reserved.

# Consolidated financial statement - Yearly results

[Unit : KRW in million]

Section		2022			2023			2024		
		Amount	Ratio	YoY	Amount	Ratio	YoY	Amount	Ratio	YoY
Pharmaceutical Business	OTC	195,820	11.0%	19.7%	193,702	10.4%	-1.1%	205,885	10.0%	6.3%
	ETC	1,115,401	62.8%	10.0%	1,138,577	61.2%	2.1%	1,141,942	55.2%	0.3%
	Affiliate	26,291	1.5%	14.8%	27,576	1.5%	4.9%	27,361	1.3%	-0.8%
	Internal sales adjustment	-16,964			-20,487			-21,111		
	<b>Total</b>	<b>1,320,548</b>	<b>74.4%</b>	<b>11.2%</b>	<b>1,339,368</b>	<b>72.0%</b>	<b>1.4%</b>	<b>1,354,077</b>	<b>65.5%</b>	<b>1.1%</b>
Consumer Goods & Healthcare		181,279	10.2%	-13.9%	215,284	11.6%	18.8%	240,621	11.6%	11.8%
Overseas Business	Export	212,808	12.0%	23.5%	241,150	13.0%	13.3%	306,484	14.8%	27.1%
	Yuhan Chemical	149,488	8.4%	8.2%	169,024	9.1%	13.1%	212,285	10.3%	25.6%
	Internal sales adjustment	-151,197			-168,240			-212,275		
	<b>Total</b>	<b>211,099</b>	<b>11.9%</b>	<b>16.5%</b>	<b>241,934</b>	<b>13.0%</b>	<b>14.6%</b>	<b>306,494</b>	<b>14.8%</b>	<b>26.7%</b>
License Income		8,745	0.5%	-83.1%	11,254	0.6%	28.7%	105,282	5.1%	835.5%
Others(Lease & Services)		54,176	3.1%	-3.8%	51,144	2.8%	-5.6%	61,317	3.0%	19.9%
<b>Total</b>		<b>1,775,847</b>	<b>100.0%</b>	<b>5.2%</b>	<b>1,858,984</b>	<b>100.0%</b>	<b>4.7%</b>	<b>2,067,791</b>	<b>100.0%</b>	<b>11.2%</b>
Operating Profit		36,029	2.0%	-25.9%	57,032	3.1%	58.3%	54,880	2.7%	-3.8%
Profit before income tax		94,926	5.3%	-24.7%	134,813	7.3%	42.0%	61,432	3.0%	-54.4%
Net Income		90,593	5.1%	-8.6%	134,241	7.2%	48.2%	55,163	2.7%	-58.9%

※ Affiliate : Yuhan Medica, Y's medi / Others : Yuhan Care, Addpharma

# Consolidated financial statement - Quarterly results

[Unit : KRW in million]

Section	1Q25	YoY	1Q24	2Q25	YoY	2Q24	3Q25	YoY	3Q24	4Q25	YoY	4Q24
OTC	54,313	15.8%	46,907			52,365			52,867			53,746
Pharmaceutical Business												
Prescription	275,468	4.9%	262,621			286,721			294,980			297,620
Affiliate	7,535	26.9%	5,936			7,285			6,473			7,667
Internal sales adjustment	-5,380		-5,289			-5,314			-5,001			-5,507
<b>Total</b>	<b>331,936</b>	<b>7.0%</b>	<b>310,175</b>			<b>341,057</b>			<b>349,319</b>			<b>353,526</b>
Consumer Goods & Healthcare	46,741	5.1%	44,454			75,220			67,430			53,517
Overseas Business												
Export	87,363	17.9%	74,107			97,180			70,067			65,130
Yuhan Chemical	64,206	31.1%	48,984			69,616			48,002			45,683
Internal sales adjustment	-64,198		-48,971			-69,619			-47,477			-46,208
<b>Total</b>	<b>87,371</b>	<b>17.9%</b>	<b>74,120</b>			<b>97,177</b>			<b>70,592</b>			<b>64,605</b>
License Income	4,009	56.6%	2,560			566			98,183			3,973
Others(Lease & Services)	21,507	61.9%	13,284			14,293			13,261			20,479
<b>Net Sales</b>	<b>491,564</b>	<b>10.6%</b>	<b>444,593</b>			<b>528,313</b>			<b>598,785</b>			<b>496,100</b>
Operating Profit	6,420	1012.1%	577			18,542			47,578			-11,817
Margin %	1.3%		0.1%			3.5%			7.9%			-2.4%
Profit before income tax	14,997	0.4%	14,941			39,166			49,780			-42,455
Net Income	10,009	-7.4%	10,812			31,912			35,542			-23,102
Margin %	2.0%		2.4%			6.0%			5.9%			-4.7%

※Affiliate : Yuhan Medica, Y's medi / Others : Yuhan Care, Addpharma

※ This report is prepared to give investors a better understanding of Yuhan Corporation.

Data in this report subject to change. Copyright © 2025 by YUHAN. All rights Reserved.



# Key Product Results



[Unit : KRW in million]

Section	Product	1Q25	YoY	1Q24
OTC	Antiplamin(pain relief medication)	8,204	-12.9%	9,417
	Elena(probiotics)	5,826	-12.5%	6,658
	Mag-B(nutritional supplement)	5,089	25.2%	4,066
	Vitamin C(nutritional supplement)	4,751	39.5%	3,407
	Bepanthen	3,708		
Prescription	Jardiance(diabetes)	25,301	13.6%	22,262
	Twynsta(hypertention)	21,271	-2.1%	21,717
	Trajenta(diabetes)	20,247	-20.0%	25,309
	Viread(hepatitis B)	17,904	0.1%	17,879
	Biktarvy(HIV)	16,749	0.3%	16,697
	Rosuvamibe(hyperlipidemia)	16,666	2.1%	16,322
	Vemlidy(hepatitis B)	15,884	20.3%	13,203
	Glivec(leukemia)	12,560	1.9%	12,323
	Cough Syrup/Tablet	12,350	-17.2%	14,914
	Femara(anticancer)	7,001	36.8%	5,117

※ This report is prepared to give investors a better understanding of Yuhan Corporation.

Data in this report subject to change. Copyright © 2025 by YUHAN. All rights Reserved.

# CDMO Business Model



• *Worldclass GMP quality system*

*(MFDS, USFDA, PMDA, TGA)*

# Capacity



Total 994,000ℓ

[Ansan Plant]  
462,700ℓ

[Hwaseong Plant]  
531,300ℓ



# Recently Concluded Agreements

## 단일판매 · 공급계약 체결

1. 판매 · 공급계약 구분		상품공급
- 체결계약명		HIV 치료제 원료의약품(HIV API) 공급계약
2. 계약내역	계약금액(원)	187,683,830,482
	최근매출액(원)	1,858,983,759,666
	매출액대비(%)	5.79
	대규모법인여부	해당
3. 계약상대		길리어드 사이언스(Gilead Sciences)
- 회사와의 관계		-
4. 판매 · 공급지역		미정
5. 계약기간	시작일	2024-09-20
	종료일	2025-09-30
6. 주요 계약조건		-
7. 계약(수주)일자		2024-09-20
8. 공시유보 관련내용	유보사유	-
	유보기한	-
9. 기타 투자판단과 관련한 중요사항		<p>1) 상기 계약금액은 USD 80,893,802입니다. (기준환율 ₩1,331.00 / \$1, 2024년 9월 19일 최초고시환율 적용)</p> <p>2) 상기 계약일자는 주문서 접수일자입니다.</p> <p>3) 상기 최근 매출액은 2023년 연결 재무제표 기준입니다.</p>
※ 관련공시	-	

## 단일판매 · 공급계약 체결


1. 판매 · 공급계약 구분		상품공급
- 체결계약명		HIV 치료제 원료의약품(HIV API) 공급계약
2. 계약내역	계약금액(원)	88,814,945,010
	최근매출액(원)	2,067,791,451,854
	매출액대비(%)	4.30
	대규모법인여부	해당
3. 계약상대		길리어드 사이언스(Gilead Sciences)
- 회사와의 관계		-
4. 판매 · 공급지역		미정
5. 계약기간	시작일	2025-05-21
	종료일	2026-12-31
6. 주요 계약조건	계약금·전금금 유부	무
	대금지급 조건 등	대금청구일로부터 30일 이내 (NET +30 days)
7. 계약(수주)일자		2025-05-21
8. 공시유보 관련내용	유보사유	-
	유보기한	-
9. 기타 투자판단과 관련한 중요사항		<p>1) 상기 계약금액은 USD 63,776,350입니다. (기준환율 ₩1,392.60 / \$1, 2025년 5월 21일 최초고시환율 적용)</p> <p>2) 상기 계약일자는 주문서 접수일자입니다.</p> <p>3) 상기 최근 매출액은 2024년 연결 재무제표 기준입니다.</p>
※ 관련공시	-	

***Gilead Sciences' HIV API, Additional Supply Agreement Signed in May 2025***

R&D

# R&D Investment & Key Status

Over 1 Trillion won intensive investment in R&D  
over the past 5 years



## Out-licensing Deals


Contract Date	Project Name	Partner(Licensor)	Contract Value	Amount received	
				Down payment	Milestone Income
2018.07	YH14618(Degenerative Disc Disease)	Spine Biopharma	\$218,150,000	\$650,000	\$2,000,000
					\$35,000,000
2018.11	Lazertinib(NSCLC)	Janssen Biotech	\$950,000,000	\$50,000,000	\$65,000,000
					\$60,000,000
2020.08	YH12852(Gut Motility Disease)	Processa Pharmaceuticals	\$410,500,000	\$2,000,000	
Total			\$1,578,650,000	\$52,650,000	\$162,000,000

※ This report is prepared to give investors a better understanding of Yuhan Corporation.

Data in this report subject to change. Copyright © 2025 by YUHAN. All rights Reserved.

# Lazertinib + Amivantamab combination therapy(1L, P3)

## [MARIPOSA]



### ※ Primary Endpoint : PFS by BICR

Median PFS	
Lazertinib + Amivantamab	23.7M
Osimertinib	16.6M
Lazertinib	18.5M

HR : 0.70


### ※ Secondary Endpoint : OS

Median OS	
Lazertinib + Amivantamab	Not reached (42.9 - NR)
Osimertinib	36.7M (33.4 - 41.0)

HR : 0.75

*The improvement in median OS is predicted to exceed 1 year*

# Lazertinib + Amivantamab combination therapy (Regulatory Approvals and Launch Status in Key Regions)




**Launched**  
(US, Japan)

**Approved**  
(Korea, EU, England,  
Canada)

**Under Regulatory Review**  
(China)



# Lazertinib + Amivantamab combination therapy(AEs)




## In the first 12 weeks

- 2-fold reduction in grade  $\geq 2$  dermatologic AEs with COCOON DM vs SoC DM(38.6% vs 76.5%)
- 2-fold reduction in grade 3 dermatologic AEs with COCOON DM vs SoC DM(4.3% vs 8.8%)
- 3-fold reduction in the number of participants who reported 2 or more different grade  $\geq 2$  dermatologic AEs with COCOON DM vs SoC DM (6% vs 18%)

*COCOON DM reduced grade  $\geq 2$  dermatologic AEs by 50% vs SoC DM*

# Lazertinib + Amivantamab SC combination therapy(P3)

## [PALOMA-3]



※ Co-primary endpoints met noninferiority Criteria( $C_{\text{through}}$  at C2D1, C2  $AUC_{D1-D15}$ )

### ※ Secondary Endpoints

	Administration Time	OS at 12M	IRR	mPFS
Lazertinib + SC Amivantamab	< 5 minutes	65%	13%	6.1M
Lazertinib + IV Amivantamab	2 ~ 5 hours	51%	66%	4.3M
<div> <div>HR</div> <div>0.62</div> <div>0.84</div> </div>				

# Superior Outcomes

May 13, 2025 / Johnson & Johnson at Bank of America Global Healthcare Conference  
(John Reed - Johnson & Johnson - Executive Vice President - Innovative Medicine, Research and Development)

“Yes. No ever since we shared our overall survival data in the frontline setting, *we're seeing the uptake really increasing exponentially.*

Just a few months ago at the European lung cancer meetings, we showed that going head to head against the standard of care, *that we were delivering this combined drug regimen of RYBREVANT plus LAZCLUZE, a chemo-free regimen, is able to extend survival by more than a year.*

And the other thing that is really insightful is that *if you look at the Kaplan-Meier curves, as time goes on, the curves between standard of care and RYBREVANT-LAZCLUZE are actually diverging even more.* It's what *we call a fish tail type of shape*, as opposed to what you might see with the standard of care, protein tyrosine kinase inhibitor, OZ, together with chemo, where the curves initially diverge, but then they converge and you get more of this banana-shaped type of thing. So we really like what we're seeing in the data.

*And then, on top of that, mind you that those data were not an optimized regimen.* That was our first shot. But *now we have a subcu* rather than an IV, which looks to be not only more convenient but also safer in terms of the injection site reactions; also, more efficacious.

And *we also have learned a lot about how to ameliorate the side effects* related to skin, thrombosis, et cetera. And so we now have an optimized protocol that we're testing in community oncology centers, particularly in this country, to gather more data.

But we feel that we're really on the right trajectory with this. And that's why we have high hopes for the molecule in both first and second-line lung.”


※ Source : [www.jnj.com](http://www.jnj.com)

# YH35324(Lesigercept)


[YH35324-101]

Changes in Serum-Free IgE Level(Median) from baseline


**A**




**C**



**B**



**D**




※ This report is prepared to give investors a better understanding of Yuhan Corporation.

Data in this report subject to change. Copyright © 2025 by YUHAN. All rights Reserved.

# YH35324(Lesigercept)

[YH35324-103, Part 1]

The Proportion of Subjects Who Achieved Complete Control



*The YH35324 6 mg/kg group exhibited a higher proportion of subjects achieving complete control (UAS7=0) compared to the omalizumab group over the course of 8 weeks.*

# Major Innovative New Drug Pipelines

\* Black : Chemical, Blue : Bio

Project	Target	Indication	Candidate	Pre-clinical	Phase I	Phase II	Phase III	Licensor	Licensee
LAZERTINIB	3G EGFR TKI	Lung cancer	Mono					GENOSCO	Johnson & Johnson Innovative Medicine
			Combination						
YH14618 (Remedisc)	TGF-β	Degenerative Disc Disease						EnsolBio sciences	SpineBiopharma
YH12852 (PCS12852)	5-HT receptor	Gut Motility Disease							Processa Pharmaceuticals
YH35324	IgE	Allergy						GI innovation	
YH32367	Her2/4-1BB	Solid Cancers						ablbio medicine for a better life	
YH42946	Her2, EGFR	Her2 Mutation Lung/Stomach Cancer						JINTS BIO	
YH35995	GCS	Gaucher's Disease, Fabry Disease						GC	
YH32364	EGFR/4-1BB	Solid Cancers						ablbio medicine for a better life	
YH45057	Androgen receptor	Prostate Cancers						Ubix Therapeutics	
YH44529	SOS1	Solid Cancers						Cyrus KANAPH	

\* This report is prepared to give investors a better understanding of Yuhan Corporation.

Data in this report subject to change. Copyright © 2025 by YUHAN. All rights Reserved.